openPR Logo
Press release

Focal Segmental Glomerulosclerosis Pipeline Drugs Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Delta4, Certa Therapeutics, Boehringer Ingelheim, River 3 Renal Corp., Dimerix Bioscience, Travere Ther

07-12-2023 07:28 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Focal Segmental Glomerulosclerosis Pipeline Drugs Analysis

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Focal Segmental Glomerulosclerosis pipeline constitutes 15+ key companies continuously working towards developing 18+ Focal Segmental Glomerulosclerosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Focal Segmental Glomerulosclerosis Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Focal Segmental Glomerulosclerosis Market.

The Focal Segmental Glomerulosclerosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Focal Segmental Glomerulosclerosis Pipeline Report: https://www.delveinsight.com/sample-request/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Focal Segmental Glomerulosclerosis treatment therapies with a considerable amount of success over the years.
• Focal Segmental Glomerulosclerosis companies working in the treatment market are Ceptur Therapeutics, Evergreen Therapeutics, Delta4, Certa Therapeutics, Boehringer Ingelheim, River 3 Renal Corp., Dimerix Bioscience, Travere Therapeutics, Inc., Horizon Therapeutics, Goldfinch, Vertex Pharmaceuticals, and others, are developing therapies for the Focal Segmental Glomerulosclerosis treatment
• Emerging Focal Segmental Glomerulosclerosis therapies in the different phases of clinical trials are- Research programme Oligonucleotides, EG-102, D4-101-02, OCX-063, BI764198, R3R 01, DMX-200, Sparsentan, Dazodalibep, GFB-887, VX-147, and others are expected to have a significant impact on the Focal Segmental Glomerulosclerosis market in the coming years.
• In June 2023, In the hunt for brand-new therapies for Focal Segmental Glomerulosclerosis (FSGS), Delta4, a cutting-edge digital drug discovery company that specialises in finding new therapeutic indications for medications with proven safety profiles, has achieved an encouraging progress
• In August 2022, the Company also completed its planned Type A meeting with the FDA to discuss a potentialsubmission for accelerated approval of sparsentan for FSGS. The FDA indicated that the DUPLEX Study asdesigned maintains the potential for full approval pending completion of the study and recommends that theCompany pursue traditional approval based on two-year eGFR slope.

Focal Segmental Glomerulosclerosis Overview
Focal and segmental glomerular capillary tuft obliteration within a creased matrix is a hallmark of Focal Segmental Glomerulosclerosis (FSGS). FSGS is divided into collapsing, tip, cellular, perihilar, and not otherwise characterised variations based on where it is located and how it behaves.

Get a Free Sample PDF Report to know more about Focal Segmental Glomerulosclerosis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Focal Segmental Glomerulosclerosis Drugs Under Different Phases of Clinical Development Include:
• Research programme Oligonucleotides: Ceptur Therapeutics
• EG-102: Evergreen Therapeutics
• D4-101-02: Delta4
• OCX-063: Certa Therapeutics
• BI764198: Boehringer Ingelheim
• R3R 01: River 3 Renal Corp.
• DMX-200: Dimerix Bioscience
• Sparsentan: Travere Therapeutics, Inc.
• Dazodalibep: Horizon Therapeutics
• GFB-887: Goldfinch
• VX-147: Vertex Pharmaceuticals

Focal Segmental Glomerulosclerosis Route of Administration
Focal Segmental Glomerulosclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Intravenous
• Subcutaneous
• Intramuscular

Focal Segmental Glomerulosclerosis Molecule Type
Focal Segmental Glomerulosclerosis Products have been categorized under various Molecule types, such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide

Focal Segmental Glomerulosclerosis Pipeline Therapeutics Assessment
• Focal Segmental Glomerulosclerosis Assessment by Product Type
• Focal Segmental Glomerulosclerosis By Stage and Product Type
• Focal Segmental Glomerulosclerosis Assessment by Route of Administration
• Focal Segmental Glomerulosclerosis By Stage and Route of Administration
• Focal Segmental Glomerulosclerosis Assessment by Molecule Type
• Focal Segmental Glomerulosclerosis by Stage and Molecule Type

DelveInsight's Focal Segmental Glomerulosclerosis Report covers around 18+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Focal Segmental Glomerulosclerosis product details are provided in the report. Download the Focal Segmental Glomerulosclerosis pipeline report to learn more about the emerging Focal Segmental Glomerulosclerosis therapies at:
https://www.delveinsight.com/sample-request/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Focal Segmental Glomerulosclerosis Therapeutics Market include:
Key companies developing therapies for Focal Segmental Glomerulosclerosis are - Dimerix, Travere, Horizon Therapeutics, Goldfinch Bio, Certa Therapeutics, ZyVersa, Vertex Pharmaceutals, B. Braun Melsungen AG, Beckman Coulter Inc. (Danaher), Baxter International Inc., ChemoCentryx Inc., Complexa Inc., Dimerix Ltd, Medtronic PLC, Pfizer Inc., Retrophin Inc., Variant Pharmaceuticals Inc., and others.

Focal Segmental Glomerulosclerosis Pipeline Analysis:
The Focal Segmental Glomerulosclerosis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Focal Segmental Glomerulosclerosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Focal Segmental Glomerulosclerosis Treatment.
• Focal Segmental Glomerulosclerosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Focal Segmental Glomerulosclerosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Focal Segmental Glomerulosclerosis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Focal Segmental Glomerulosclerosis drugs and therapies-
https://www.delveinsight.com/sample-request/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Focal Segmental Glomerulosclerosis Pipeline Market Drivers
• Surge of interest in developing new therapies for FSGS, renaissance in clinical research in nephrology are some of the important factors that are fueling the Focal Segmental Glomerulosclerosis Market.

Focal Segmental Glomerulosclerosis Pipeline Market Barriers
• However, the etiology and pathogenesis of Focal Segmental Glomerulosclerosis are very complex, high cost associated with the disease and other factors are creating obstacles in the Focal Segmental Glomerulosclerosis Market growth.

Scope of Focal Segmental Glomerulosclerosis Pipeline Drug Insight
• Coverage: Global
• Key Focal Segmental Glomerulosclerosis Companies: Ceptur Therapeutics, Evergreen Therapeutics, Delta4, Certa Therapeutics, Boehringer Ingelheim, River 3 Renal Corp., Dimerix Bioscience, Travere Therapeutics, Inc., Horizon Therapeutics, Goldfinch, Vertex Pharmaceuticals, and others
• Key Focal Segmental Glomerulosclerosis Therapies: Research programme Oligonucleotides, EG-102, D4-101-02, OCX-063, BI764198, R3R 01, DMX-200, Sparsentan, Dazodalibep, GFB-887, VX-147, and others
• Focal Segmental Glomerulosclerosis Therapeutic Assessment: Focal Segmental Glomerulosclerosis current marketed and Focal Segmental Glomerulosclerosis emerging therapies
• Focal Segmental Glomerulosclerosis Market Dynamics: Focal Segmental Glomerulosclerosis market drivers and Focal Segmental Glomerulosclerosis market barriers

Request for Sample PDF Report for Focal Segmental Glomerulosclerosis Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Focal Segmental Glomerulosclerosis Report Introduction
2. Focal Segmental Glomerulosclerosis Executive Summary
3. Focal Segmental Glomerulosclerosis Overview
4. Focal Segmental Glomerulosclerosis- Analytical Perspective In-depth Commercial Assessment
5. Focal Segmental Glomerulosclerosis Pipeline Therapeutics
6. Focal Segmental Glomerulosclerosis Late Stage Products (Phase II/III)
7. Focal Segmental Glomerulosclerosis Mid Stage Products (Phase II)
8. Focal Segmental Glomerulosclerosis Early Stage Products (Phase I)
9. Focal Segmental Glomerulosclerosis Preclinical Stage Products
10. Focal Segmental Glomerulosclerosis Therapeutics Assessment
11. Focal Segmental Glomerulosclerosis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Focal Segmental Glomerulosclerosis Key Companies
14. Focal Segmental Glomerulosclerosis Key Products
15. Focal Segmental Glomerulosclerosis Unmet Needs
16 . Focal Segmental Glomerulosclerosis Market Drivers and Barriers
17. Focal Segmental Glomerulosclerosis Future Perspectives and Conclusion
18. Focal Segmental Glomerulosclerosis Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Focal Segmental Glomerulosclerosis Market https://www.delveinsight.com/report-store/focal-segmental-glomerulosclerosis-fsgs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Focal Segmental Glomerulosclerosis-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Focal Segmental Glomerulosclerosis Epidemiology https://www.delveinsight.com/report-store/focal-segmental-glomerulosclerosis-fsgs-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Focal Segmental Glomerulosclerosis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Monkeypox Market https://www.delveinsight.com/report-store/monkeypox-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Monkeypox Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Pars Planitis Market
https://www.delveinsight.com/report-store/pars-plantis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products

Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market https://www.delveinsight.com/report-store/zika-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Opioid Use Disorder Market https://www.delveinsight.com/report-store/opioid-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Opioid Use Disorder (OUD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Focal Segmental Glomerulosclerosis Pipeline Drugs Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Delta4, Certa Therapeutics, Boehringer Ingelheim, River 3 Renal Corp., Dimerix Bioscience, Travere Ther here

News-ID: 3127210 • Views:

More Releases from DelveInsight Business Research

Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) Market Poised for Transformation with FDA Approvals and Expanding Pipeline, Finds DelveInsight
Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) Market Pois …
Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) Market Summary NF1-PN Market Set to Grow Beyond USD 380 Million by 2034 driven by rising diagnosed cases, better awareness, advanced diagnostics, and genetic testing. In the US alone, ~97,000 diagnosed NF1 cases were reported in 2023, expected to increase by 2034. Treatment remains challenging-surgery is often complex, risky, and prone to recurrence, leaving significant unmet needs, especially in pediatric patients with inoperable PNs. Current
DelveInsight Unveils Competitive Landscape Assessment: Unlocking Opportunities in Dissolvable Microneedle Technology (dMTS) Space
DelveInsight Unveils Competitive Landscape Assessment: Unlocking Opportunities i …
DelveInsight, a leading business consulting and market intelligence firm in healthcare, announces the release of its latest Competitive Landscape Assessment Case Study, showcasing opportunities in the dissolvable microneedle technology (dMTS) space. This in-depth analysis highlights how strategic evaluations and tailored solutions can enable global healthcare organizations to expand product offerings, secure intellectual property, and strengthen their competitive positions in the rapidly growing drug delivery market. Gain firsthand access to a complimentary
Competitive Intelligence in the Hematology Domain: Driving Strategic Success through Long-Term Engagement with DelveInsight
Competitive Intelligence in the Hematology Domain: Driving Strategic Success thr …
DelveInsight, a leader in healthcare consulting and competitive intelligence, has recently showcased its success in a long-term engagement for competitive intelligence support within the hematology domain. This case study highlights how timely, in-depth competitive intelligence empowered a Europe-based client to refine strategies, strengthen launch preparedness, and maintain a leadership position in the face of intense competition. The rapidly evolving field of hematological malignancies, including Acute Myeloid Leukemia (AML), Multiple Myeloma, and
Hepatic Encephalopathy Market Expected to Gain Momentum Through 2034, According to DelveInsight
Hepatic Encephalopathy Market Expected to Gain Momentum Through 2034, According …
DelveInsight's "Hepatic Encephalopathy Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Hepatic Encephalopathy, historical and forecasted epidemiology as well as the Hepatic Encephalopathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. To Know in detail about the Hepatic Encephalopathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hepatic Encephalopathy Market Forecast https://www.delveinsight.com/sample-request/hepatic-encephalopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the

All 5 Releases


More Releases for Focal

Focal Epilepsy Market New Product Development & Latest Trends
Introduction Focal epilepsy, the most common form of epilepsy worldwide, originates in specific regions of the brain and often presents with partial seizures. Affecting millions of people globally, focal epilepsy remains a pressing neurological challenge with significant clinical and economic impact. Increasing diagnosis rates, technological advances in imaging and neurostimulation, and new pharmacological approaches are fueling rapid changes in the treatment landscape. As healthcare systems place greater emphasis on effective long-term management
Focal Segmental Glomerulosclerosis Market Size Report 2024
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033. Focal Segmental Glomerulosclerosis Drugs Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance. The Market Size Is Expected To Reach $22.41 billion In
3D FOCAL LINES SPATULA TECHNOLOGY for SYGMALIFT
Focal Ultrasounds in three-dimensional (3D) technology expand to the Face Lifting and V Facing. This innovation is able to treat volume that contains every conceivable plane (X, Y, Z angles) within the region of interest such as Double Chin or Cheeks. While there is no doubt that there are advantages to volume treatment in 2.5 Seconds only, it delivers more power and add clinical benefit to target submental and jawlines
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics - Pipeline Analysis 2018
Focal segmental glomerulosclerosis (FSGS) is a glomerular disease, which is characterized by scarring or sclerosis in the kidney. Scarring damages the limited number of glomeruli in the initial stages. It is more common in males than in females, anad is very common in African American population. Download the sample report @ https://www.pharmaproff.com/request-sample/1090 FSGS can be caused by many diseases like diabetes, sickle cell disease, and HIV infection. It is categorized into two
Focal Segmental Glomerulosclerosis (FSGS) Market Report 2018: Segmentation by Di …
Global Focal Segmental Glomerulosclerosis (FSGS) market research report provides company profile for Variant Pharmaceuticals, Inc., GlaxoSmithKline plc., Novartis AG, ChemoCentryx, Inc., Retrophin, Inc., AbbVie, Inc., AstraZeneca plc., Pfizer, Inc., Sanofi S.A, Teva Pharmaceutical Industries Ltd. and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth
Africa Energy Week – Three Different Focal Points, One Conference
Africa’s development in oil and gas has significantly increased over the last few years; Ghana’s Jubilee field, first discovered in 2007, is now producing 70,000 barrels a day and may climb to 120,000 by the end of the year. With much of its oil for export, the country’s economic growth is climbing at a rapid rate, and many are looking to follow suit. Local content has since been a hot